A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model

Anti-PD-1/PD-L1 immunotherapy has limited efficacy in hepatocellular carcinoma (HCC) and does not benefit all patients. A FAK inhibitor (VS-4718) has been reported to improve the microenvironment in some tumors. This study aimed to investigate the effect of the combination of the FAK inhibitor VS471...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yuhua, Wang, Yufeng, Liu, Nanbin, Qi, Ran, Xu, Yan, Li, Kun, Feng, Yu, Shi, Baomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804348/
https://www.ncbi.nlm.nih.gov/pubmed/35115949
http://dx.doi.org/10.3389/fphar.2021.820446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804348/
https://www.ncbi.nlm.nih.gov/pubmed/35115949
http://dx.doi.org/10.3389/fphar.2021.820446

Ejemplares similares